• Earlier in 2026, Schrödinger launched an early access version of Bunsen, an agentic AI co-scientist that integrates AI and physics-based simulation to plan, execute, and interpret complex molecular discovery workflows, supported by co-engineered infrastructure from NVIDIA and Google Cloud.
• By making Schrödinger’s validated computational methods accessible through natural-language interaction and automating large-scale discovery workflows, Bunsen could broaden usage beyond computational chemists and materially increase how intensively existing customers rely on the company’s software platform.
• Next, we’ll look at how Bunsen’s AI co-scientist capabilities might influence Schrödinger’s investment narrative around software adoption and scalability.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Schrödinger Investment Narrative Recap

To be a shareholder in Schrödinger, you need to believe its physics-based software can become a core tool across drug discovery while the company manages persistent losses and margin pressure. The Bunsen launch speaks directly to the near term catalyst of deeper software adoption and higher usage within existing accounts, but does little to reduce key risks around ongoing net losses and dependence on pharma and biotech budgets in the current funding climate.

Among recent developments, the multi‑year Manas AI agreement is especially relevant alongside Bunsen. Both point to Schrödinger’s push to embed its physics-based methods inside AI‑driven discovery workflows, which could support higher recurring software revenue if customers scale usage. Together with collaborations like Lilly TuneLab, these moves frame Bunsen less as a one‑off product launch and more as part of a broader effort to make Schrödinger’s platform integral to partners’ discovery pipelines.

Yet while Bunsen may deepen usage, investors should also be aware that intensifying competition and emerging open‑source tools could...

Schrödinger's narrative projects $349.6 million revenue and $23.4 million earnings by 2029. This requires 11.1% yearly revenue growth and a $126.9 million earnings increase from -$103.5 million today.

Uncover how Schrödinger's forecasts yield a $20.88 fair value, a 37% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue to reach about US$424,000,000 and earnings near US$78,900,000 by 2029, so Bunsen’s launch could either reinforce or challenge those views depending on how you weigh that upside against rising competitive pressure from big tech and open source tools.

Explore 4 other fair value estimates on Schrödinger - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Schrödinger research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Schrödinger research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Schrödinger's overall financial health at a glance.

No Opportunity In Schrödinger?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.